A Single Dose Study to Test Two Tafamidis Tablet Formulations in Healthy Adult Participants
A Single Dose Study to Test Two Tafamidis Tablet Formulations in Healthy Adult Participants. A Phase 1, Open-Label, Randomized, Crossover, Single Dose Study to Estimate the Relative Bioavailability of Variant 12.2 mg Tafamidis Free Acid Tablets and Proposed Commercial 12.2 mg Tafamidis Free Acid Tablets Administered Under Fasted Conditions
in Healthy Adult Participants.
Category & Conditions: Neurological Diseases and Conditions
Medicine: VYNDAQEL® (TAFAMIDIS MEGLUMINE) CAPSULES AND VYNDAMAX™ (TAFAMIDIS) CAPSULES
ClinicalTrials.gov Identifier (NCT): NCT05482308
Protocol ID: B3461102
PrintDownloadOpen Plain Language Summary Result: Click here